Pharsight

Axid generic

Axid is an acid reducer owned by Braintree and was approved for market on May 25, 2004. Its active ingredient is nizatidine, available in solution; oral dosage forms.

When will Axid generic be available?

The patent for Axid, US6930119, is set to expire on July 17, 2022. Following this date, generic versions of Axid may become available, assuming there are no additional patents or exclusivities protecting this drug.

Axid uses

Axid, with its active ingredient nizatidine, is used to decrease the amount of acid produced in the stomach. This acid reducer is effective in treating and preventing ulcers in the stomach and intestines. It is also used to treat conditions where the stomach produces too much acid.

Axid patent expiration

Axid's last standing patent, US6930119, is set to expire on July 17, 2022. Following the patent expiry, we could expect the release of Axid generic. Below are the details of the patent:

Axid dosage

Want to ask something?